Blanket Purchase Agreement V797D30296-36E79719A0025

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs, to Astellas Pharma US, Inc., a foreign-owned for-profit pharmaceutical manufacturer. The BPA has a ceiling value of $296,500.00 and a period of performance through October 6, 2025. The purpose of this BPA is to facilitate the procurement of the oncology drugs XTANDI and XOSPATA by the VA and potentially other federal agencies. This BPA was established...

This Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Astellas Pharma US, Inc., a foreign-owned pharmaceutical manufacturer, provides for the procurement of drugs and pharmaceuticals, including specialty oncology medications. The $3.5 billion contract, awarded in 2021 with a period of performance through 2026, was established under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) and is designated as a multiple award vehicle. Under this FSS...

The Department of Veterans Affairs awarded a blanket purchase agreement to Cardinal Health 414, LLC to supply XOFIGO radiopharmaceutical. With a potential value of $367,238, the single award BPA facilitates delivery of the product to Veterans Integrated Service Network 2 through March 2021. No set-aside provisions were applied. Subsequently, Cardinal Health received a $34,676 firm fixed price call against the BPA. Performance will take place in Dublin, Ohio through March 2021. As the sole...

The Defense Health Agency awarded a blanket purchase agreement to Progenics Pharmaceuticals Inc. to procure PILARIFY (PIFLUFOLASTAT F-18) injection, an imaging agent used in positron emission tomography scans to aid in the detection and localization of prostate cancer. The BPA has a potential value of $250,000 and period of performance through April 2027. Multiple firm fixed price call contracts have been placed against the BPA at various medical treatment facilities for delivery of PILARIFY...

The Defense Health Agency (DHA) awarded a Blanket Purchase Agreement (BPA) to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., for the delivery of PYLARIFY (piflufolastat F-18) injection, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The BPA has a ceiling value of $1,000,000 and a period of performance through January 31, 2028. The contract is not set aside for small businesses. Under this BPA, the DHA...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the Department of Veterans Affairs (VA) to Daiichi Sankyo, Inc., a pharmaceutical manufacturer. The single-award BPA, valued at $80,206.95, provides a mechanism for VA healthcare facilities nationwide to efficiently procure the specialty drug pexidartinib (marketed as TURALIO) in various dosage forms. Pexidartinib is used to treat tenosynovial giant cell tumor, a rare disease, in eligible veteran patients....

The Department of Veterans Affairs National Acquisition Center awarded a single-award Blanket Purchase Agreement to Urogen Pharma Inc. The BPA has a potential value of $1.5 million and expires on February 3, 2021. It was established on October 2, 2020 to procure Jelmyto, a treatment for low-grade upper tract urothelial cancer. As the sole awardee, Urogen Pharma will provide its product Jelmyto to the VA National Acquisition Center through this BPA. Jelmyto is an FDA-approved medication for the...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Advanced Accelerator Applications USA Inc., a large, foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The $23.4 million single-award BPA is under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of February 3, 2025. The BPA is for the procurement of LOCAMETZ and NETSPOT, two...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to HRA Pharma America, Inc. as the prime contractor. The BPA has a period of performance from June 10, 2025 to June 9, 2026 and a ceiling value of $1,386,062.00. The BPA is for the procurement of the pharmaceutical products Lysodren and Metopirone. No set-asides were used for this single-award contract. The purpose of this BPA is to establish a contract vehicle through which the...

This Blanket Purchase Agreement (BPA) is a federal contract Indefinite Delivery Vehicle (IDV) awarded by the National Acquisition Center, a civilian agency, to Merck Sharp & Dohme LLC, doing business as Merck. The BPA has a ceiling value of $15,000,000 and an ultimate completion date of August 8, 2025. It was awarded on August 9, 2022 and is not set-aside. The primary purpose of this BPA is the procurement of the pharmaceutical product Welireg (belzutifan) from Merck, a major...